Niagen Bioscience Inc
NASDAQ:NAGEBiotechnology
+$0.11 today
- Market cap
- $153.64M
- Beta
- 2.06
- P/E (TTM)
- 14.9
- EPS (TTM)
- $0.23
Volume 0.52M
Average 0.86M
Dividends
Niagen Bioscience Inc dividends
Review the payout history, yield, and how well earnings and cash flow support the dividend.
Dividends
Dividend history, growth & yield
Yield
0.00%
Annual Div/Share
$0.00
Payout Ratio
0.0%
Frequency
—
Shareholder Yield
0.16%
Next Ex-Date
Not announced
Next Payment
—
Analysis
The current indicated dividend yield is 0.00%. The payout ratio is 0.0%, so compare payout growth against earnings coverage.
Competitor dividends
How does Niagen Bioscience Inc compare as an income stock?
Compare dividend yield, payout ratios, and buybacks with similar companies.
Competitor Dividends
Peer payout, dividend, and buyback comparison
| Company | Market Cap | Dividend Yield | Annual Dividend | Payout Ratio | Buyback Yield |
|---|---|---|---|---|---|
KalVista Pharmaceuticals, Inc. NASDAQ:KALV | $1.44B | 0.00% | $0.00 | 0.00% | 0.00% |
Corvus Pharmaceuticals, Inc. NASDAQ:CRVS | $897.52M | 0.00% | $0.00 | 0.00% | 0.00% |
Rigel Pharmaceuticals, Inc. NASDAQ:RIGL | $837.18M | 0.00% | $0.00 | 0.00% | 0.47% |
Olema Pharmaceuticals, Inc. NASDAQ:OLMA | $662.30M | 0.00% | $0.00 | 0.00% | 0.00% |
Zevra Therapeutics, Inc. NASDAQ:ZVRA | $540.30M | 0.00% | $0.00 | 0.00% | 0.00% |
REGENXBIO Inc. NASDAQ:RGNX | $505.18M | 0.00% | $0.00 | 0.00% | 0.00% |
Prothena Corporation plc NASDAQ:PRTA | $419.01M | 0.00% | $0.00 | 0.00% | 1.64% |
Keros Therapeutics, Inc. NASDAQ:KROS | $202.13M | 0.00% | $0.00 | 0.00% | 0.00% |
Akebia Therapeutics, Inc. NASDAQ:AKBA | $131.67M | 0.00% | $0.00 | 0.00% | 0.00% |
Questions
Dividend questions
Common questions about NAGE's dividend, answered from reported figures.
Does NAGE stock pay dividends?
Niagen Bioscience Inc (NAGE) currently pays a dividend. The indicated dividend per share is 0.00 USD and the dividend yield is 0.00%.
Is NAGE's dividend covered?
The payout ratio is 0.0%, so compare that against earnings and free cash flow before relying on the dividend.
Continue the stock analysis
Jump to another research area for this company.